Member Directory - Pharmaceutical Advisory Board

Chair: Charles Flexner

Objectives:

  • Engage industry in conversations and serve as a key resource to identify barriers in development and to encourage production of LA/ER ARV’s
  • Identify additional experts who can make meaningful contributions to LA/ER topic-specific focus groups, including the generation of educational materials and consensus publications.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Receives consulting fees from Gilead Sciences, Merck, Janssen, ViiV Healthcare. Has an ownership interest in Navigen LLC, and receives grant funding from Gilead Sciences.

Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie.

Conflict of Interest: Dr. Cohen is an employee and stockholder of AbbVie.

Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs.

Conflict of Interest: None disclosed.

Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina.

Conflict of Interest: None disclosed.

Kati Vandermeulen, M.SC., is a Senior Director, Compound Development Team Leader at Janssen Infectious Diseases Research and Development in Beerse Belgium.

Conflict of Interest: Has no real or apparent conflicts of interest to report.